OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.94 Million TWD | -101.11% |
| 2022 | 143.46 Million TWD | 356.57% |
| 2021 | 31.42 Million TWD | -75.78% |
| 2020 | 129.72 Million TWD | 3.16% |
| 2019 | 125.76 Million TWD | -22.06% |
| 2018 | 161.36 Million TWD | 27.25% |
| 2017 | 126.8 Million TWD | 48.84% |
| 2016 | 85.2 Million TWD | -23.22% |
| 2015 | 110.96 Million TWD | 55.5% |
| 2014 | 71.36 Million TWD | -48.36% |
| 2013 | 138.2 Million TWD | 42.95% |
| 2012 | 96.67 Million TWD | 33.64% |
| 2011 | 72.34 Million TWD | 91.7% |
| 2010 | 37.73 Million TWD | -24.07% |
| 2009 | 49.7 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 36.1 Million TWD | 216.08% |
| 2024 Q2 | 42.26 Million TWD | 17.08% |
| 2023 Q4 | -31.1 Million TWD | -3838.22% |
| 2023 FY | -1.59 Million TWD | -101.11% |
| 2023 Q1 | 18.03 Million TWD | 368.84% |
| 2023 Q3 | 832 Thousand TWD | -94.48% |
| 2023 Q2 | 15.06 Million TWD | -16.46% |
| 2022 Q3 | 46.34 Million TWD | -13.81% |
| 2022 Q1 | 48.7 Million TWD | 3510.92% |
| 2022 FY | 143.46 Million TWD | 356.57% |
| 2022 Q4 | -6.7 Million TWD | -114.47% |
| 2022 Q2 | 53.76 Million TWD | 10.38% |
| 2021 Q1 | 29.76 Million TWD | -16.54% |
| 2021 FY | 31.42 Million TWD | -75.78% |
| 2021 Q4 | -1.42 Million TWD | -109.34% |
| 2021 Q3 | 15.29 Million TWD | 9312.65% |
| 2021 Q2 | -166 Thousand TWD | -100.56% |
| 2020 Q4 | 35.66 Million TWD | 35.15% |
| 2020 Q2 | 21 Million TWD | -55.0% |
| 2020 FY | 129.72 Million TWD | 3.16% |
| 2020 Q1 | 46.67 Million TWD | 40.31% |
| 2020 Q3 | 26.38 Million TWD | 25.64% |
| 2019 Q1 | 29.16 Million TWD | -28.33% |
| 2019 Q3 | 38.26 Million TWD | 52.65% |
| 2019 Q2 | 25.06 Million TWD | -14.05% |
| 2019 Q4 | 33.26 Million TWD | -13.06% |
| 2019 FY | 125.76 Million TWD | -22.06% |
| 2018 Q2 | 29.41 Million TWD | -30.08% |
| 2018 Q3 | 49.19 Million TWD | 67.24% |
| 2018 Q4 | 40.69 Million TWD | -17.27% |
| 2018 FY | 161.36 Million TWD | 27.25% |
| 2018 Q1 | 42.06 Million TWD | 51.35% |
| 2017 Q3 | 39.45 Million TWD | 18.57% |
| 2017 Q4 | 27.79 Million TWD | -29.55% |
| 2017 FY | 126.8 Million TWD | 48.84% |
| 2017 Q1 | 26.28 Million TWD | 55.27% |
| 2017 Q2 | 33.27 Million TWD | 26.57% |
| 2016 FY | 85.2 Million TWD | -23.22% |
| 2016 Q3 | 3.59 Million TWD | -86.9% |
| 2016 Q4 | 16.93 Million TWD | 371.48% |
| 2016 Q2 | 27.42 Million TWD | -26.4% |
| 2016 Q1 | 37.25 Million TWD | 27.61% |
| 2015 FY | 110.96 Million TWD | 55.5% |
| 2015 Q4 | 29.19 Million TWD | 0.0% |
| 2015 Q3 | 29.19 Million TWD | 11.07% |
| 2015 Q2 | 26.28 Million TWD | 0.0% |
| 2015 Q1 | 26.28 Million TWD | 70.8% |
| 2014 Q1 | 20.29 Million TWD | -27.03% |
| 2014 Q2 | 20.29 Million TWD | 0.0% |
| 2014 Q4 | 15.39 Million TWD | 0.0% |
| 2014 Q3 | 15.39 Million TWD | -24.15% |
| 2014 FY | 71.36 Million TWD | -48.36% |
| 2013 Q2 | 41.29 Million TWD | 0.0% |
| 2013 Q1 | 41.29 Million TWD | 68.68% |
| 2013 Q3 | 27.8 Million TWD | -32.66% |
| 2013 Q4 | 27.8 Million TWD | 0.0% |
| 2013 FY | 138.2 Million TWD | 42.95% |
| 2012 FY | 96.67 Million TWD | 33.64% |
| 2012 Q3 | 24.48 Million TWD | 0.0% |
| 2012 Q4 | 24.48 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 FY | 72.34 Million TWD | 91.7% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2010 FY | 37.73 Million TWD | -24.07% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 49.7 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 746.6 Million TWD | 99.605% |
| Apex Medical Corp. | 152.17 Million TWD | 98.063% |
| Applied BioCode Corporation | -164.19 Million TWD | 101.795% |